PCA3 gene expression in prostate cancer tissue in a Chinese population: Quantification by real-time FQ-RT-PCR based on exon 3 of PCA3

Experimental and Molecular Pathology

Volumn 89, Issue 1, 2010, Pages 58-62

  Tao, Z ^a,b   Shen, M ^b   Zheng, Y ^b   Mao, X ^b   Chen, Z ^b   Yin, Y ^a   Yu, K ^c   Weng, Z ^b   Xie, H ^b   Li, C ^b   Wu, X ^b   Hu, Y ^b   Zhang, X ^b   Wang, O ^b   Song, Q ^b   Yu, Z ^b  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^c THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

PCA3 (DD3); Prostate cancer; Real time FQ RT PCR

Indexed keywords

MESSENGER RNA; PROSTATE CANCER ANTIGEN 3; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CANCER TISSUE; CHINESE; CONTROLLED STUDY; EXON; FLUORESCENT QUANTITATIVE REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; GENE EXPRESSION; GLEASON SCORE; HUMAN; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; PROSTATE CANCER; PROSTATE HYPERTROPHY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

ANTIGENS, NEOPLASM; ASIAN CONTINENTAL ANCESTRY GROUP; EXONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM STAGING; PROGNOSIS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 77954031316     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2010.01.008     Document Type: Article

References (23)

1. Bussemakers M.J., et al. DD3: a new prostate-specific gene, highly over-expressed in prostate cancer. Cancer Res. 1999, 59:5975-5979.
2. Burger M.J., et al. Expression analysis of delta-catenin and prostate-specific membrane antigen: their potential as diagnostic markers for prostate cancer. Int. J. Cancer. 2002, 100:228-237.
3. PCA3, a very sensitive and specific marker to detect prostate tumors. Cancer Res. 2002, 62:2695-2698.
4. Epstein J.I., et al. Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term follow up. J. Urol. 1993, 50:135-141.
5. Gandini O., et al. Is DD3 a new prostate-specific gene?. Anticancer Res. 2003, 23:305-308.
6. Hessels, et al. DD3PCA3-based molecular urine analysis for the diagnosis of prostate cancer. Eur. Urol. 2003, 44:8-16.
7. Hessels, et al. The use of PCA3 in the diagnosis of prostate cancer. Nature Reviews Urology 2009, 6:255-261.
8. Jemal A., et al. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58:71-96.
9. Kallakury B.V., et al. Telomerase activity in human benign prostate tissue and prostatic adenocarcinomas. Diagn. Mol. Pathol. 1997, 6:192-198.
10. Lu-Yao G.L., et al. An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. JAMA 1993, 269:2633-2636.
11. Lin B., et al. Prostate-localized and androgen-regulated expression of the membrane bound serine protease TMPRSS2. Cancer Res. 1999, 59:4180-4184.
12. Murphy G.P., et al. Evaluation and comparison of two new prostate carcinoma markers: free-prostate specific antigen and prostate specific membrane antigen. Cancer 1996, 78:809-818.
13. Magee J.A., et al. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res. 2001, 61:5692-5696.
14. Oettgen P., et al. PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate specific antigen gene expression. J. Biol. Chem. 2000, 275:1216-2125.
15. Paulson D.F., et al. Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results. J. Urol. 1990, 144:1180-1184.
16. Pannek J., Partin A.W. Prostate-specific antigen: what's new in 1997. Oncology 1997, 11:1273-1278.
17. Pound C.R., et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy: patterns of recurrence and cancer control. Urol. Clin. 1997, 24:395-406.
18. Scates D.K., et al. Detection of telomerase activity in human prostate: a diagnostic marker for prostatic cancer?. Br. J. Urol. 1997, 80:263-268.
19. Schiffer E. Biomarkers for prostate cancer. World J. Urol. 2007, 25:557-562.
20. Väänänen R.M., et al. Quantitative real-time RT-PCR assay for PCA3. Clin. Biochem. 2008, 4:103-108.
21. Walsh P.C., et al. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10years. J. Urol. 1994, 152:1831-1836.
22. Zincke H., et al. Long-term (15years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J. Urol. 1994, 152:1850-1857.
23. Zhou M., et al. Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am. J. Surg. Pathol. 2002, 26:926-931.